Literature DB >> 33907997

Characterization of Protein Glycoforms at Intact Level by Orbitrap Mass Spectrometry.

Dan Bach Kristensen1, Trine Meiborg Sloth2, Martin Ørgaard2, Pernille Foged Jensen2.   

Abstract

Intact mass analysis of proteins is simple, fast, and specific, and it effectively provides structural insight into the proteoforms or variants of the analyzed protein. For instance, the multiple glycoforms of recombinant monoclonal antibodies can be effectively analyzed by intact mass spectrometry (MS). A recent development in the Orbitrap technology has made this platform particularly well suited for analysis of large intact biomolecules, and here we describe procedures for performing intact mass analysis of intact glycoproteins using the Orbitrap platform, with the aim of identifying and quantitating the glycoforms. Emphasis is placed on the analysis of biopharmaceutical immunoglobulins (IgGs), but the procedures can be extended to other glycoproteins as needed.

Keywords:  Antibody; Biopharmaceutical; Glycoform; Glycoprotein; IgG; Native intact mass spectrometry; Orbitrap

Year:  2021        PMID: 33907997     DOI: 10.1007/978-1-0716-1241-5_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies.

Authors:  Veysel Kayser; Naresh Chennamsetty; Vladimir Voynov; Kurt Forrer; Bernhard Helk; Bernhardt L Trout
Journal:  Biotechnol J       Date:  2011-01       Impact factor: 4.677

Review 2.  Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.

Authors:  Liming Liu
Journal:  J Pharm Sci       Date:  2015-04-14       Impact factor: 3.534

3.  Dynamics of ions of intact proteins in the Orbitrap mass analyzer.

Authors:  Alexander Makarov; Eduard Denisov
Journal:  J Am Soc Mass Spectrom       Date:  2009-04-05       Impact factor: 3.109

4.  From protein complexes to subunit backbone fragments: a multi-stage approach to native mass spectrometry.

Authors:  Mikhail E Belov; Eugen Damoc; Eduard Denisov; Philip D Compton; Stevan Horning; Alexander A Makarov; Neil L Kelleher
Journal:  Anal Chem       Date:  2013-11-20       Impact factor: 6.986

5.  High-fidelity mass analysis unveils heterogeneity in intact ribosomal particles.

Authors:  Michiel van de Waterbeemd; Kyle L Fort; Dmitriy Boll; Maria Reinhardt-Szyba; Andrew Routh; Alexander Makarov; Albert J R Heck
Journal:  Nat Methods       Date:  2017-01-23       Impact factor: 28.547

Review 6.  Characterization of therapeutic antibodies and related products.

Authors:  Alain Beck; Elsa Wagner-Rousset; Daniel Ayoub; Alain Van Dorsselaer; Sarah Sanglier-Cianférani
Journal:  Anal Chem       Date:  2012-12-14       Impact factor: 6.986

7.  Charge Variant Analysis of Monoclonal Antibodies Using Direct Coupled pH Gradient Cation Exchange Chromatography to High-Resolution Native Mass Spectrometry.

Authors:  Florian Füssl; Ken Cook; Kai Scheffler; Amy Farrell; Stefan Mittermayr; Jonathan Bones
Journal:  Anal Chem       Date:  2018-03-12       Impact factor: 6.986

8.  High-resolution mass spectrometry of small molecules bound to membrane proteins.

Authors:  Joseph Gault; Joseph A C Donlan; Idlir Liko; Jonathan T S Hopper; Kallol Gupta; Nicholas G Housden; Weston B Struwe; Michael T Marty; Todd Mize; Cherine Bechara; Ya Zhu; Beili Wu; Colin Kleanthous; Mikhail Belov; Eugen Damoc; Alexander Makarov; Carol V Robinson
Journal:  Nat Methods       Date:  2016-02-22       Impact factor: 28.547

Review 9.  Glycan analysis of therapeutic glycoproteins.

Authors:  Lei Zhang; Shen Luo; Baolin Zhang
Journal:  MAbs       Date:  2015-11-24       Impact factor: 5.857

10.  Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry.

Authors:  Florian Füssl; Anne Trappe; Ken Cook; Kai Scheffler; Oliver Fitzgerald; Jonathan Bones
Journal:  MAbs       Date:  2018-11-11       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.